Dual Immune Checkpoint Blockade in Unresectable HCC (Transcript)
COSMIC-312 Trial Overview
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoi
Phase 3 COSMIC-312 Study in Advanced HCC
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma | International Journal of Clinical Oncology
File:"Cosmic Cliffs" in the Carina Nebula (NIRCam Compass Image) (2022-031).png - Wikimedia Commons
柳叶刀重磅丨COSMIC-312：肝癌免疫治疗之谜- 知乎
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review - ScienceDirect
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
晚期肝癌：卡博替尼+阿替利珠单抗的3 期研究结果- whyes 的博客
Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma - Gray - 2023 - Liver Cancer International - Wiley Online Library
Phase 3 COSMIC-312 Study in Advanced HCC
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology
![COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram](https://www.researchgate.net/publication/351523048/figure/fig4/AS:1028856655908867@1622309950788/COSMIC-312-Study-Design-Reproduced-with-permission-from-Kelley-et-al-91_Q320.jpg "COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram")
COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram
Cabozantinib Plus Atezolizumab Extends PFS for Frontline HCC in COSMIC-312 Trial
ESMO - Eur. Oncology on X: "#ESMOasiaweek21: New data for management of #hepatocellularcarcinoma. The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration ➡️
HCC CONNECT on X: "#ESMOasiaweek21: this is the place to be for clinical practice changing in advanced #hepatocellularcarcinoma! After ESMO Asia 2019 with #IMbrave150, we are waiting for the presentation of COSMIC-312
![COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram](https://www.researchgate.net/publication/351523048/figure/tbl1/AS:1028856655908868@1622309950810/Ongoing-clinical-trials-of-cabozantinib-in-HCC_Q320.jpg "COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram")
COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram
晚期肝癌：卡博替尼+阿替利珠单抗的3 期研究结果- whyes 的博客
晚期肝癌：卡博替尼+阿替利珠单抗的3 期研究结果- whyes 的博客
![COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram](https://www.researchgate.net/publication/351523048/figure/fig4/AS:1028856655908867@1622309950788/COSMIC-312-Study-Design-Reproduced-with-permission-from-Kelley-et-al-91.png "COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram")
COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
